B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.
B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.